[Pharmacological profile of roflumilast].

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Archivos de Bronconeumologia

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0300-2896(10)70052-1PMID 21316552
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A phosphodiesterase 4 inhibitor, roflumilast N-oxide, inhibits human lung fibroblast functions in vitro.

  2010cited by this paper
• The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.

  2010cited by this paper
• Forskolin increases angiogenesis through the coordinated cross-talk of PKA-dependent VEGF expression and Epac-mediated PI3K/Akt/eNOS signaling.

  2009cited by this paper
• Current status of research on osteoporosis in COPD: a systematic review

  2009cited by this paper
• Reduced adiposity and high-fat diet-induced adipose inflammation in mice deficient for phosphodiesterase 4B.

  2009cited by this paper
• The role of animal models in the pharmacological evaluation of emerging anti-inflammatory agents for the treatment of COPD.

  2009cited by this paper
• Effects of Roflumilast, a Phosphodiesterase-4 Inhibitor, on Hypoxia- and Monocrotaline-Induced Pulmonary Hypertension in Rats

  2009cited by this paper
• Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin‐induced lung injury

  2009cited by this paper
• Inhibition of Osteoblast Functions by IKK/NF-κB in Osteoporosis

  2009cited by this paper
• The role of the PDE4D cAMP phosphodiesterase in the regulation of glucagon‐like peptide‐1 release

  2009cited by this paper
• Inhibition of PI3Kdelta restores glucocorticoid function in smoking-induced airway inflammation in mice.

  2009cited by this paper
• The metabolic syndrome, diabetes and lung dysfunction.

  2008cited by this paper
• Pulmonary hypertension in COPD

  2008cited by this paper
• Mechanisms of cigarette smoke-induced COPD: insights from animal models.

  2008cited by this paper
• The selective MMP‐12 inhibitor, AS111793 reduces airway inflammation in mice exposed to cigarette smoke

  2008cited by this paper
• Animal models of chronic obstructive pulmonary disease.

  2008cited by this paper
• Effect of roflumilast on inflammatory cells in the lungs of cigarette smoke-exposed mice

  2008cited by this paper
• Phosphodiesterase 3 and 4 comprise the major cAMP metabolizing enzymes responsible for insulin secretion in INS-1 (832/13) cells and rat islets.

  2008cited by this paper
• Insulin Resistance and inflammation—A Further Systemic Complication of COPD

  2007cited by this paper
• Rolipram, a phosphodiesterase 4 inhibitor, prevented cancellous and cortical bone loss by inhibiting endosteal bone resorption and maintaining the elevated periosteal bone formation in adult ovariectomized rats.

  2007cited by this paper
• Squamous metaplasia amplifies pathologic epithelial-mesenchymal interactions in COPD patients.

  2007cited by this paper
• Dose‐Proportional Intraindividual Single‐ and Repeated‐Dose Pharmacokinetics of Roflumilast, an Oral, Once‐Daily Phosphodiesterase 4 Inhibitor

  2007cited by this paper
• Roflumilast inhibits leukocyte‐endothelial cell interactions, expression of adhesion molecules and microvascular permeability

  2007cited by this paper
• Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model.

  2006cited by this paper
• A phosphodiesterase 4 inhibitor inhibits matrix protein deposition in airways in vitro.

  2006cited by this paper
• Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells

  2005cited by this paper
• Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke.

  2005cited by this paper
• Phosphodiesterase 4 inhibition reduces skeletal muscle atrophy

  2005cited by this paper
• The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro.

  2005cited by this paper
• COPD, a multicomponent disease: implications for management.

  2005cited by this paper
• Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4).

  2004cited by this paper
• The nature of small-airway obstruction in chronic obstructive pulmonary disease.

  2004cited by this paper
• Preferential Inhibition of T Helper 1, but Not T Helper 2, Cytokines in Vitro by L-826,141 [4-{2-(3,4-Bisdifluromethoxyphenyl)-2-{4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl}-3-methylpyridine-1-oxide], a Potent and Selective Phosphodiesterase 4 Inhibitor

  2004cited by this paper
• Cytokines modulate cilomilast response in lung fibroblasts.

  2004cited by this paper
• Cigarette smoke alters chromatin remodeling and induces proinflammatory genes in rat lungs.

  2004cited by this paper
• PDE4 inhibitors attenuate fibroblast chemotaxis and contraction of native collagen gels.

  2002cited by this paper
• Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro.

  2001cited by this paper
• Bleomycin-induced chronic lung damage does not resemble human idiopathic pulmonary fibrosis.

  2001cited by this paper
• Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD.

  1997cited by this paper
• Influence of selective phosphodiesterase inhibitors on human neutrophil functions and levels of cAMP and Cai

  1991cited by this paper

• Cyclic nucleotide phosphodiesterases as drug targets.

  2025cites this paper
• Gut microbiota, metabolites, and pulmonary hypertension: Mutual regulation and potential therapies.

  2025cites this paper
• Air pollution and diseases: signaling, G protein-coupled and Toll like receptors.

  2025cites this paper
• The Possible Nephroprotective Effect of Roflumilast Ameliorating Glycerol -Induced Myoglobinuric Acute Renal Injury in Rabbits Model

  2020cites this paper
• [Limitations of current treatment: unmet needs in the treatment of COPD].

  2010cites this paper